Ritter Pharmaceuticals (RTTR) Reports Q3 Loss of $0.40/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ritter Pharmaceuticals Provides Third Quarter 2015 Financial Results and Business Update
November 17, 2015 8:31 AM ESTLOS ANGELES--(BUSINESS WIRE)-- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (Ritter Pharmaceuticals or the Company), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today reported financial results and a business update for the third quarter ended September 30, 2015.
Recent Highlights
Closed initial public offering on June 29, 2015 generating gross proceeds of $20 million Strengthened senior leadership team with key appointments: William J. Sandborn, M.D. to Medical Advisory Board AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical... More